niacinamide has been researched along with Cell Transformation, Neoplastic in 34 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Cell Transformation, Neoplastic: Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.
| Excerpt | Relevance | Reference |
|---|---|---|
| " One patient with advanced-stage lung adenocarcinoma, who was treated with oral sorafenib, demonstrated a near-complete clinical and radiographic remission for 5 years." | 7.80 | Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. ( Amann, J; Araujo, L; Carbone, DP; Greulich, H; Horn, L; Imielinski, M; Kaplan, B; Meyerson, M; Schiller, J; Villalona-Calero, MA, 2014) |
| "Sorafenib is a potent drug for advanced HCC with multikinase inhibition activity." | 5.43 | Sorafenib treatment during partial hepatectomy reduces tumorgenesis in an inflammation-associated liver cancer model. ( Axelrod, JH; Divon, MS; Galun, E; Lanton, T; Peretz, T; Salmon, A; Sonnenblick, A; Zahavi, T, 2016) |
| "Well-differentiated hepatocellular carcinomas developed in nude mice given injections of the TAMH line, and these appeared similar to the primary liver tumors seen in TGF-alpha transgenic mice with regard to histology and strong expression of mouse and human TGF-alpha, insulin-like growth factor II, and alpha-fetoprotein mRNAs." | 5.29 | Autonomous growth in serum-free medium and production of hepatocellular carcinomas by differentiated hepatocyte lines that overexpress transforming growth factor alpha 1. ( Cveklova, K; Fausto, N; Merlino, G; Mosinger, B; Wu, JC, 1994) |
| " One patient with advanced-stage lung adenocarcinoma, who was treated with oral sorafenib, demonstrated a near-complete clinical and radiographic remission for 5 years." | 3.80 | Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. ( Amann, J; Araujo, L; Carbone, DP; Greulich, H; Horn, L; Imielinski, M; Kaplan, B; Meyerson, M; Schiller, J; Villalona-Calero, MA, 2014) |
| "Sorafenib is a non-selective multiple kinase inhibitor with proven antiproliferative effects in thyroid, renal and hepatocellular carcinoma." | 2.50 | Targeted treatment of ovarian cancer--the multiple - kinase - inhibitor sorafenib as a potential option. ( Haybaeck, J; Petru, E; Smolle, E; Taucher, V, 2014) |
| "Sorafenib is a potent drug for advanced HCC with multikinase inhibition activity." | 1.43 | Sorafenib treatment during partial hepatectomy reduces tumorgenesis in an inflammation-associated liver cancer model. ( Axelrod, JH; Divon, MS; Galun, E; Lanton, T; Peretz, T; Salmon, A; Sonnenblick, A; Zahavi, T, 2016) |
| "Approximately 27% of breast cancers express high LMW-E protein levels, which significantly correlates with poor survival." | 1.38 | LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients. ( Akli, S; Duong, MT; Hunt, KK; Keyomarsi, K; Liu, W; Lu, Y; Mills, GB; Wei, C; Wingate, HF; Yi, M, 2012) |
| "Well-differentiated hepatocellular carcinomas developed in nude mice given injections of the TAMH line, and these appeared similar to the primary liver tumors seen in TGF-alpha transgenic mice with regard to histology and strong expression of mouse and human TGF-alpha, insulin-like growth factor II, and alpha-fetoprotein mRNAs." | 1.29 | Autonomous growth in serum-free medium and production of hepatocellular carcinomas by differentiated hepatocyte lines that overexpress transforming growth factor alpha 1. ( Cveklova, K; Fausto, N; Merlino, G; Mosinger, B; Wu, JC, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (14.71) | 18.7374 |
| 1990's | 1 (2.94) | 18.2507 |
| 2000's | 6 (17.65) | 29.6817 |
| 2010's | 20 (58.82) | 24.3611 |
| 2020's | 2 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Mierzejewska, P | 1 |
| Kunc, M | 1 |
| Zabielska-Kaczorowska, MA | 1 |
| Kutryb-Zajac, B | 1 |
| Pelikant-Malecka, I | 1 |
| Braczko, A | 1 |
| Jablonska, P | 1 |
| Romaszko, P | 1 |
| Koszalka, P | 1 |
| Szade, J | 1 |
| Smolenski, RT | 1 |
| Slominska, EM | 1 |
| Zhao, C | 1 |
| Zhang, H | 1 |
| Zhou, J | 1 |
| Liu, Q | 1 |
| Lu, Q | 1 |
| Zhang, Y | 1 |
| Yu, X | 1 |
| Wang, S | 1 |
| Liu, R | 1 |
| Pu, Y | 1 |
| Yin, L | 1 |
| Li, XF | 1 |
| Chen, C | 2 |
| Xiang, DM | 1 |
| Qu, L | 1 |
| Sun, W | 1 |
| Lu, XY | 1 |
| Zhou, TF | 1 |
| Chen, SZ | 1 |
| Ning, BF | 1 |
| Cheng, Z | 1 |
| Xia, MY | 1 |
| Shen, WF | 1 |
| Yang, W | 1 |
| Wen, W | 1 |
| Lee, TKW | 1 |
| Cong, WM | 1 |
| Wang, HY | 1 |
| Ding, J | 1 |
| Poot, AJ | 1 |
| van der Wildt, B | 1 |
| Stigter-van Walsum, M | 1 |
| Rongen, M | 1 |
| Schuit, RC | 1 |
| Hendrikse, NH | 1 |
| Eriksson, J | 1 |
| van Dongen, GA | 1 |
| Windhorst, AD | 1 |
| Batra, V | 1 |
| Kislay, B | 1 |
| Imielinski, M | 1 |
| Greulich, H | 1 |
| Kaplan, B | 1 |
| Araujo, L | 1 |
| Amann, J | 1 |
| Horn, L | 1 |
| Schiller, J | 1 |
| Villalona-Calero, MA | 1 |
| Meyerson, M | 1 |
| Carbone, DP | 1 |
| Smolle, E | 1 |
| Taucher, V | 1 |
| Petru, E | 1 |
| Haybaeck, J | 1 |
| Galuppo, R | 1 |
| Maynard, E | 1 |
| Shah, M | 1 |
| Daily, MF | 1 |
| Spear, BT | 1 |
| Gedaly, R | 1 |
| Groß, C | 1 |
| Steiger, K | 1 |
| Sayyed, S | 1 |
| Heid, I | 1 |
| Feuchtinger, A | 1 |
| Walch, A | 1 |
| Heß, J | 1 |
| Unger, K | 1 |
| Zitzelsberger, H | 1 |
| Settles, M | 1 |
| Schlitter, AM | 1 |
| Dworniczak, J | 1 |
| Altomonte, J | 1 |
| Ebert, O | 1 |
| Schwaiger, M | 1 |
| Rummeny, E | 1 |
| Steingötter, A | 1 |
| Esposito, I | 1 |
| Braren, R | 1 |
| Zahavi, T | 1 |
| Lanton, T | 1 |
| Divon, MS | 1 |
| Salmon, A | 1 |
| Peretz, T | 1 |
| Galun, E | 1 |
| Axelrod, JH | 1 |
| Sonnenblick, A | 1 |
| Ju, HQ | 1 |
| Zhan, G | 1 |
| Huang, A | 1 |
| Sun, Y | 1 |
| Wen, S | 1 |
| Yang, J | 1 |
| Lu, WH | 1 |
| Xu, RH | 1 |
| Li, J | 1 |
| Li, Y | 1 |
| Garcia-Manero, G | 1 |
| Huang, P | 1 |
| Hu, Y | 1 |
| Arnault, JP | 1 |
| Wechsler, J | 1 |
| Escudier, B | 1 |
| Spatz, A | 1 |
| Tomasic, G | 1 |
| Sibaud, V | 1 |
| Aractingi, S | 1 |
| Grange, JD | 1 |
| Poirier-Colame, V | 1 |
| Malka, D | 1 |
| Soria, JC | 1 |
| Mateus, C | 1 |
| Robert, C | 1 |
| Karreth, FA | 1 |
| DeNicola, GM | 1 |
| Winter, SP | 1 |
| Tuveson, DA | 1 |
| Tong, TQ | 1 |
| Rohde, D | 1 |
| Peter, S | 1 |
| Denoyer, D | 1 |
| Greguric, I | 1 |
| Roselt, P | 1 |
| Neels, OC | 1 |
| Aide, N | 1 |
| Taylor, SR | 1 |
| Katsifis, A | 1 |
| Dorow, DS | 1 |
| Hicks, RJ | 1 |
| Prazeres, H | 1 |
| Couto, JP | 1 |
| Rodrigues, F | 1 |
| Vinagre, J | 1 |
| Torres, J | 1 |
| Trovisco, V | 1 |
| Martins, TC | 1 |
| Sobrinho-Simões, M | 1 |
| Soares, P | 1 |
| Caronia, LM | 1 |
| Phay, JE | 1 |
| Shah, MH | 1 |
| Matsuda, Y | 1 |
| Ichida, T | 1 |
| Fukumoto, M | 1 |
| Salinas-Sánchez, AS | 1 |
| Giménez-Bachs, JM | 1 |
| Serrano-Oviedo, L | 1 |
| Nam Cha, S | 1 |
| Sánchez-Prieto, R | 1 |
| Surjana, D | 1 |
| Halliday, GM | 1 |
| Martin, AJ | 1 |
| Moloney, FJ | 1 |
| Damian, DL | 1 |
| Duong, MT | 1 |
| Akli, S | 1 |
| Wei, C | 1 |
| Wingate, HF | 1 |
| Liu, W | 1 |
| Lu, Y | 1 |
| Yi, M | 1 |
| Mills, GB | 1 |
| Hunt, KK | 1 |
| Keyomarsi, K | 1 |
| Dar, AC | 1 |
| Das, TK | 1 |
| Shokat, KM | 1 |
| Cagan, RL | 1 |
| Matsuse, M | 1 |
| Mitsutake, N | 1 |
| Tanimura, S | 1 |
| Ogi, T | 1 |
| Nishihara, E | 1 |
| Hirokawa, M | 1 |
| Fuziwara, CS | 1 |
| Saenko, VA | 1 |
| Suzuki, K | 1 |
| Miyauchi, A | 1 |
| Yamashita, S | 1 |
| Friedman, SL | 1 |
| Beckman, M | 1 |
| Kiser, KF | 1 |
| Colombi, M | 1 |
| Moroni, C | 1 |
| Gollob, JA | 1 |
| Wilhelm, S | 1 |
| Carter, C | 1 |
| Kelley, SL | 1 |
| Dai, JM | 1 |
| Wang, ZY | 1 |
| Sun, DC | 1 |
| Lin, RX | 1 |
| Wang, SQ | 1 |
| Althaus, FR | 1 |
| Lawrence, SD | 1 |
| He, YZ | 1 |
| Sattler, GL | 1 |
| Tsukada, Y | 1 |
| Pitot, HC | 1 |
| Johnson, GS | 2 |
| Chiang, PK | 1 |
| Wu, JC | 1 |
| Merlino, G | 1 |
| Cveklova, K | 1 |
| Mosinger, B | 1 |
| Fausto, N | 1 |
| Fernandez-Pol, JA | 1 |
| Bono, VH | 1 |
| Boothman, DA | 1 |
| Schlegel, R | 1 |
| Pardee, AB | 1 |
| Kuroki, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer[NCT02363647] | 10 participants (Actual) | Interventional | 2015-01-31 | Terminated (stopped due to No Current Funding) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for niacinamide and Cell Transformation, Neoplastic
| Article | Year |
|---|---|
Targeted treatment of ovarian cancer--the multiple - kinase - inhibitor sorafenib as a potential option.
Topics: Antineoplastic Agents; Cell Transformation, Neoplastic; Clinical Trials as Topic; Disease Progressio | 2014 |
Progress in the management of advanced renal cell carcinoma (RCC).
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2010 |
Role of BRAF in thyroid oncogenesis.
Topics: Benzenesulfonates; Cell Transformation, Neoplastic; Genetic Predisposition to Disease; Humans; Mutat | 2011 |
Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; C | 2011 |
[Role of mitogen-activated protein kinase (MAPK) in the sporadic renal cell carcinoma].
Topics: Antigens, Neoplasm; Antineoplastic Agents; Benzenesulfonates; Carbonic Anhydrase IX; Carbonic Anhydr | 2012 |
Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Transformation, Neopl | 2006 |
Anticarcinogenic potential of DNA-repair modulators.
Topics: Animals; Antibiotics, Antineoplastic; Carcinogens; Cell Transformation, Neoplastic; DNA Damage; DNA | 1988 |
[Chemical carcinogenesis in vitro. 2].
Topics: Animals; Carcinogens; Cell Transformation, Neoplastic; Culture Techniques; Dactinomycin; DNA; Genes; | 1970 |
2 trials available for niacinamide and Cell Transformation, Neoplastic
| Article | Year |
|---|---|
In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.
Topics: Adult; Aged; Animals; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Benzenesulfonates | 2011 |
Oral nicotinamide reduces actinic keratoses in phase II double-blinded randomized controlled trials.
Topics: Aged; Aged, 80 and over; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cell Transformation, Neopl | 2012 |
24 other studies available for niacinamide and Cell Transformation, Neoplastic
| Article | Year |
|---|---|
An unusual nicotinamide derivative, 4-pyridone-3-carboxamide ribonucleoside (4PYR), is a novel endothelial toxin and oncometabolite.
Topics: Animals; Carcinogens; Cell Line, Tumor; Cell Membrane Permeability; Cell Transformation, Neoplastic; | 2021 |
Metabolomic transition trajectory and potential mechanisms of N-nitrosomethylbenzylamine induced esophageal squamous cell carcinoma in rats.
Topics: Animals; Carcinogens; Carcinogens, Environmental; Cell Transformation, Neoplastic; Dimethylnitrosami | 2022 |
Chronic inflammation-elicited liver progenitor cell conversion to liver cancer stem cell with clinical significance.
Topics: Animals; Antigens, Differentiation; Antineoplastic Agents; Cell Self Renewal; Cell Transformation, N | 2017 |
[¹¹C]Sorafenib: radiosynthesis and preclinical evaluation in tumor-bearing mice of a new TKI-PET tracer.
Topics: Animals; Carbon Radioisotopes; Cell Line, Tumor; Cell Transformation, Neoplastic; Male; Mice; Neopla | 2013 |
Mitigation of gamma-radiation induced abasic sites in genomic DNA by dietary nicotinamide supplementation: metabolic up-regulation of NAD(+) biosynthesis.
Topics: Animals; Base Sequence; Cell Transformation, Neoplastic; Dietary Supplements; Gamma Rays; Genome; Ma | 2013 |
Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Amino Acid Substitution; Antineoplastic Agents; Cell T | 2014 |
Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/β-catenin pathways.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cel | 2014 |
Model Matters: Differences in Orthotopic Rat Hepatocellular Carcinoma Physiology Determine Therapy Response to Sorafenib.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Biomarkers; Biopsy; Carcinoma, Hepatocellul | 2015 |
Sorafenib treatment during partial hepatectomy reduces tumorgenesis in an inflammation-associated liver cancer model.
Topics: Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP-Bindin | 2016 |
ITD mutation in FLT3 tyrosine kinase promotes Warburg effect and renders therapeutic sensitivity to glycolytic inhibition.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Cell Line; Cell Transformation, Neoplastic; | 2017 |
Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; | 2009 |
C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
Topics: Animals; Benzenesulfonates; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell | 2009 |
High-contrast PET of melanoma using (18)F-MEL050, a selective probe for melanin with predominantly renal clearance.
Topics: Animals; Autoradiography; Cell Line, Tumor; Cell Transformation, Neoplastic; Contrast Media; Female; | 2010 |
LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients.
Topics: Acinar Cells; Animals; Benzenesulfonates; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Ce | 2012 |
Chemical genetic discovery of targets and anti-targets for cancer polypharmacology.
Topics: Animals; Benzenesulfonates; Cell Transformation, Neoplastic; Disease Models, Animal; Drosophila mela | 2012 |
Functional characterization of the novel BRAF complex mutation, BRAF(V600delinsYM) , identified in papillary thyroid carcinoma.
Topics: 3T3 Cells; Amino Acid Substitution; Animals; Benzenesulfonates; Carcinoma; Carcinoma, Papillary; Cel | 2013 |
Focus.
Topics: Animals; Cell Transformation, Neoplastic; Epithelial-Mesenchymal Transition; Hepatic Veno-Occlusive | 2012 |
Going Ku Ku on Bax.
Topics: Acetylation; Animals; Antigens, Nuclear; Apoptosis; bcl-2-Associated X Protein; Cell Transformation, | 2004 |
Isolation and characterization of dominant and recessive IL-3-independent hematopoietic transformants.
Topics: Aminacrine; Benzenesulfonates; Butadienes; Cell Transformation, Neoplastic; Clone Cells; Frameshift | 2006 |
SIRT1 interacts with p73 and suppresses p73-dependent transcriptional activity.
Topics: Acetylation; Apoptosis; bcl-2-Associated X Protein; Cell Transformation, Neoplastic; DNA-Binding Pro | 2007 |
Effects of altered [ADP-ribose]n metabolism on expression of fetal functions by adult hepatocytes.
Topics: Adenosine Diphosphate Ribose; Animals; Cell Differentiation; Cell Transformation, Neoplastic; Cells, | 1982 |
1-methylnicotinamide and NAD metabolism in normal and transformed normal rat kidney cells.
Topics: Animals; Cell Line; Cell Transformation, Neoplastic; Kidney; NAD; Niacinamide; Rats; S-Adenosylhomoc | 1981 |
Autonomous growth in serum-free medium and production of hepatocellular carcinomas by differentiated hepatocyte lines that overexpress transforming growth factor alpha 1.
Topics: alpha-Fetoproteins; Animals; Carcinoma, Hepatocellular; Cell Division; Cell Line; Cell Transformatio | 1994 |
Control of growth by picolinic acid: differential response of normal and transformed cells.
Topics: Cell Division; Cell Line; Cell Survival; Cell Transformation, Neoplastic; Chelating Agents; Depressi | 1977 |